Zacks Investment Research cut shares of Affimed (NASDAQ:AFMD) from a buy rating to a hold rating in a research report report published on Thursday.
According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “
Shares of AFMD opened at $2.18 on Thursday. Affimed has a 1 year low of $1.15 and a 1 year high of $2.85. The company has a quick ratio of 5.58, a current ratio of 5.61 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $131.02, a PE ratio of -2.79 and a beta of 2.30.
A number of hedge funds have recently added to or reduced their stakes in AFMD. Dimensional Fund Advisors LP increased its holdings in Affimed by 817.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 122,773 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Affimed during the 3rd quarter valued at $658,000. Virtu Financial LLC increased its holdings in Affimed by 483.0% during the 4th quarter. Virtu Financial LLC now owns 85,562 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 70,886 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in Affimed during the 4th quarter valued at $136,000. 27.86% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Affimed (AFMD) Stock Rating Lowered by Zacks Investment Research” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/04/16/affimed-afmd-stock-rating-lowered-by-zacks-investment-research.html.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.